Avacta Group Plc · LSE:AVCT
Avacta — Investor Presentation (June 2020)
21 slides from Avacta's investor presentation, Jun 5, 2020
Slide 1: Avacta Group plc June 2020 Placing Presentation
pre|CISION TM Avacta Group plc June 2020 Placing Presentation © Avacta Group plc 1
Slide 2: Disclaimer: Important Notice
Disclaimer: Important Notice pre|CISION TM No representation or warranty, expressed or implied, is made or given by or on behalf of Avacta Group plc (the “Company” and, together with its subsidiaries and subsidiary undertakings, the “Group”) or any of its directors or any other person as to the accu
Slide 3: Introduction
pre|CISION TM Introduction © Avacta Group plc 3
Slide 4: Avacta Group Overview
Avacta Group Overview pre|CISION TM Diagnostics Division • Based in Wetherby, Yorkshire • R&D Centre and plc Headquarters • 40 (inc 22 PhDs) scientists/technicians LSE: AVCT ~£400M market capitalisation • In-house product development • Global partnerships (undisclosed) Therapeutics Division • Based
Slide 5: Avacta's Proprietary Platform Technologies
Avacta’s Proprietary Platform Technologies pre|CISION TM Affimer: An Alternative to Antibodies pre|CISION: targeted chemotherapies • Based on a naturally occurring protein • pre|CISION is based on chemistry that is (stefin A) and engineered to display a binding specifically cut by an enzyme called f
Slide 6: Strong Base and Substantial Untapped Potential to Grow Long Term Sustainable Shareholder Value
Strong Base and Substantial Untapped Potential to Grow Long Term Sustainable Shareholder Value pre|CISION TM Therapeutics Diagnostics Pre-clinical and clinical pipeline Product pipeline and services Licensing/development partnerships/JVs Licensing/OEM pre|CISION TM Fully human antibody mimetic FAP a
Slide 7: COVID-19 Antigen Test
pre|CISION TM COVID-19 Antigen Test © Avacta Group plc 7
Slide 8: SARS-COV-2 Rapid Antigen Test: Collaboration with Cytiva
SARS-COV-2 Rapid Antigen Test: Collaboration with Cytiva (formerly GE Healthcare) pre|CISION TM Have I Got Coronavirus ? VS Have I Had Coronavirus ? ~1-2 weeks for body to develop Blood sample antibodies Person infected with coronavirus Saliva sample Nasal or throat swab “PCR” tests Lab test results
Slide 9: COVID-19 Antigen Testing Market: Not Just a Short Term Opportunity
COVID-19 Antigen Testing Market: pre|CISION TM Not Just a Short Term Opportunity The consensus view is that hundreds of millions of antigen tests will be required per month to support the fight against the pandemic and initial easing of the lock-down during 2020, and to deal with the long term chall
Slide 10: SARS-COV-2 Rapid Antigen Test Update
SARS-COV-2 Rapid Antigen Test Update pre|CISION TM (formerly GE Healthcare Life Sciences) Development partner for rapid, saliva based COVID-19 antigen test Development partner for high-end, high-throughput laboratory COVID-19 test Direct-to-consumer distribution partner for COVID-19 antigen test and
Slide 11: Therapeutics Pipeline
pre|CISION TM Therapeutics Pipeline © Avacta Group plc 11
Slide 12: preCISION Pro-drugs AVA6000 Pro-doxorubicin
pre|CISION Pro-drugs AVA6000 Pro-doxorubicin pre|CISION TM AVA6000 addresses the safety issues of a $1bn generic chemotherapy Background Targeting of Drug to Tumour Spares Heart Tissue Doxorubicin has been a standard of care 18x more active chemotherapy in the treatment for advanced soft tissue sarc
Slide 13: AVA6000 Pro-doxorubicin Efficacy
AVA6000 Pro-doxorubicin Efficacy pre|CISION TM AVA6000 Pro-doxorubicin permits higher doses than the MTD for doxorubicin resulting in better anti-tumour activity in mouse xenograft model Effect on Tumour Size Effect on Survival AVA6000 Control 2 mg/kg 9 mg/kg 12 mg/kg Control 2 mg/kg 9 mg/kg 12 mg/k
Slide 14: Wider preCISION Pro-drug Opportunity
Wider pre|CISION Pro-drug Opportunity pre|CISION TM pre|CISION can be widely applied to a range of chemotherapies in a market expected to be worth $56.5bn (2024) (CAGR 11.50%) driven by increased cancer detection rates Example: Velcade Ideal for pre|CISION tumour activation to create • Bortezomib (V
Slide 15: Tumour Microenvironment Activated Drug Conjugates (TMAC)
Tumour Microenvironment Activated Drug Conjugates (TMACTM) pre|CISION TM Combination of Avacta’s two proprietary platforms to deliver a chemotherapy and an immunotherapy in a single drug molecule Chemo “Warhead” Affimer Immunotherapy • Released in the tumour • Supports the immune by the preCISION li
Slide 16: Lead TMAC Programme: AVA04-VbP
Lead TMAC Programme: AVA04-VbP pre|CISION TM In the colorectal tumour model CT26 VbP TMACs produce full regression of the tumours Control AVA04 anti-PD-L1 | VbP TMAC Undisclosed Affimer | VbP TMAC • Two TMAC formats were tested in a CT26 • In the case of the PD-L1/VbP TMAC, this tumour model. The TM
Slide 17: Partnered Therapeutic Programmes
Partnered Therapeutic Programmes pre|CISION TM Fully funded programmes with partners and retention of the commercial rights to the Affimer molecules outside of the collaboration Multi-target development partnership and Three target deal to develop Affimer-drug licensing deal worth up to $310m with $
Slide 18: Partnered Therapeutic Programmes
Partnered Therapeutic Programmes pre|CISION TM Fully funded programmes with partners and retention of the commercial rights to the Affimer molecules outside of the collaboration Established JV January 2020 to develop next First therapeutic partnership established in generation engineered stem cell t
Slide 19: Use of Proceeds (2020-23) of the Heavily Oversubscribed Placing, 5 June 2020
Use of Proceeds (2020-23) of the Heavily Oversubscribed Placing, 5 June 2020 pre|CISION TM Accelerated scale-up of diagnostics business and expansion of therapeutics pipeline Rapid Scale-up of Diagnostics Business, approx. £10 million: • Working capital for the COVID-19 testing opportunity • Expansi
Slide 20: Summary
Summary pre|CISION TM In-house and partnered pipelines of novel cancer therapies based on two proprietary platform technologies: Affimer® - antibody mimetic platform - and preCISIONTM - tumour targeted chemotherapy platform. In-house and partnered pipeline of diagnostics based on the Affimer platfor
Slide 21: Brokers and Contacts
pre|CISION TM Joint Broker and Nomad Joint Broker FinnCap, London Zeus Capital, London Geoff Nash / Giles Rolls/ Tim Redfern Nick Cowles, John Goold [email protected] [email protected] [email protected] [email protected] www.finncap.com www.zeuscapital.com T +44 (0) 207 220 0500